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Histone post-translational modifications (hPTMs) generate
a complex combinatorial code that has been implicated
with various pathologies, including cancer. Dissecting such
a code in physiological and diseased states may be ex-
ploited for epigenetic biomarker discovery, but hPTM anal-
ysis in clinical samples has been hindered by technical
limitations. Here, we developed a method (PAThology tis-
sue analysis of Histones by Mass Spectrometry - PAT-H-
MS) that allows to perform a comprehensive, unbiased and
quantitative MS-analysis of hPTM patterns on formalin-
fixed paraffin-embedded (FFPE) samples. In pairwise com-
parisons, histone extracted from formalin-fixed paraffin-
embedded tissues showed patterns similar to fresh frozen
samples for 24 differentially modified peptides from histone
H3. In addition, when coupled with a histone-focused version
of the super-SILAC approach, this method allows the accu-
rate quantification of modification changes among breast
cancer patient samples. As an initial application of the
PAThology tissue analysis of Histones byMass Spectrometry
method, we analyzed breast cancer samples, revealing sig-
nificant changes in histone H3 methylation patterns among
Luminal A-like and Triple Negative disease subtypes. These
results pave the way for retrospective epigenetic studies that
combine the power of MS-based hPTM analysis with the
extensive clinical information associated with formalin-
fixed paraffin-embedded archives. Molecular & Cellular
Proteomics 15: 10.1074/mcp.M115.054510, 866–877, 2016.
Histone post-translational modifications (hPTMs)1 generate
a complex combinatorial code that plays a critical role during
the physiological and pathological regulation of gene expres-
sion (1). Alterations in histone modification patterns have been
linked with various diseases, including cancer, often as a result
of the aberrant expression or localization of histone mod-
ifying enzymes (2). Therefore, accurately dissecting hPTM
patterns in normal and diseased tissues could yield epigenetic
biomarkers useful for prognostic, diagnostic, and therapeutic
purposes. Immunohistochemistry studies have shown the po-
tential of this strategy (3, 4), but they were limited to the
analysis of only a few hPTMs. In addition, despite their sen-
sitivity and ease of use, antibody-based assays are hindered
by issues such as the difficulty in detecting adjacent modifi-
cations and the limited linearity of the signal. As an alternative
to traditional antibody-based methods, in recent years MS
has become the elective method to analyze hPTMs, thanks to
its unbiased nature, accuracy and its ability to quantitate
modifications and detect their combinations. Various MS-
based workflows optimized for hPTM analysis have been
developed (5), but most of the studies focused on cell lines
and animal tissue, whereas the potential offered by the anal-
ysis of clinical samples has been left largely unexploited. In
particular, the MS-based analysis of hPTMs from formalin-
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fixed paraffin-embedded (FFPE) samples has never been
addressed.
Paraffin embedding following fixation in buffered formalin is
the storage method of choice for clinical specimens, thus
representing an invaluable source of clinical samples linked to
retrospective patient information. Large formalin-fixed paraf-
fin embedded (FFPE) archives, which are available in many
hospitals, have been successfully exploited for DNA and RNA
analyses, including chromatin immunoprecipitation (6, 7).
However, the extensive protein cross-linking generated by
formaldehyde fixation has hindered the proteomic study of
this type of tissue. This problem has been addressed and
overcome only recently in global proteomic studies by taking
advantage of extraction protocols based on heat-induced
antigen retrieval techniques derived from immunohistochem-
istry (8, 9). Moreover, a few studies showed the possibility to
globally analyze protein post-translational modifications, such
as glycosylation and phosphorylation, from fixed and embed-
ded tissues (10–12).
Here, we report for the first time the successful application
of MS-based analysis of hPTMs to human clinical samples,
focusing in particular on the development and validation of a
method (PAT-H-MS) to extract histones from FFPE tissues in
yield and purity sufficient to enable the subsequent use of a
proteomic workflow optimized for hPTM analysis (13). By
using this method we were able to profile in a quantitative
manner 24 distinct modified histone peptides from human
FFPE breast cancer samples belonging to different subtypes,
identifying differences in histone methylation patterns of po-
tential clinical relevance. Thus, PAT-H-MS represents a valid
approach for hPTM analysis of clinical samples.
EXPERIMENTAL PROCEDURES
Preparation of Frozen and FFPE Tissues—Leukemic blasts were
isolated from acute promyelocytic leukemia transgenic mice and 1 
106 cells were i.v. injected in a syngenic recipient mouse to induce
secondary leukemia (14). After massive splenomegaly was estab-
lished, the mouse was sacrificed and its spleen was divided into two
portions. One portion was washed and homogenized in 5 ml ice-cold
phosphate buffered saline (PBS: 0.8% NaCl; 0.02% KCl; 0.02%
KH2PO4; 0.2% Na2HPO4, pH 7.4) using a Dounce homogenizer,
obtaining spleen cells that were counted, pelleted by centrifugation,
rapidly frozen, and stored at 80 °C until use. The other half of the
spleen was washed in PBS and incubated for 16 h at room temper-
ature in a 4% paraformaldehyde solution. The fixed spleen was then
routinely dehydrated with increasing concentrations of ethanol (70%,
80%, 90 and 100%) and subsequently included in paraffin using a
tissue processor (Leica ASP300). Frozen cells and FFPE tissues
were prepared similarly from mouse liver. Experimental procedures
involving animals complied with the Guidelines of the Italian Na-
tional Institute of Health, and were approved by the Institutional
Ethical Committee.
Invasive breast cancer specimens were obtained from 23 patients
with duct invasive carcinoma not otherwise specified (supplemental
Fig. S3A and supplemental Table S3), who were subjected to mas-
tectomy or breast conserving surgery. The patients provided informed
consent and this study was approved by the Ethical Committee of the
European Institute of Oncology. Tumor samples were collected and
snap frozen or fixed 4% formalin and embedded in paraffin. Tumor
cells accounted for 50% or more of the samples, as evaluated histo-
logically. The assessment of hormone receptors and Her-2 status, as
well as the Ki-67 labeling index was ascertained by immunohisto-
chemistry, according to the ASCO/CAP recommendations, using the
FDA-approved anti-ER/PgR (PharmDX, Dako) and Her-2 (Herceptest,
Dako), as well as the anti-Ki-67 antibody MIB-1. Breast cancer sub-
types were defined according to the 2013 S. Gallen consensus con-
ference recommendations, using immunohistochemical surrogates
as follows: Luminal A-like: ER and/or PgR(), HER2(-), Ki67  20%;
Luminal B-like: ER and/or PgR(), HER2(-), Ki67  20; Triple Nega-
tive: ER, PgR and HER2(-), irrespective of Ki67 score; HER2-positive:
HER2(), irrespective of ER, PgR or Ki67. ER/PgR positivity was
defined as 1% of immunoreactive neoplastic cells; HER2 positivity
was defined as 10% of neoplastic cells with strong and continuous
staining of the cell membrane (3 by immunohistochemistry) and/or
amplified by in situ hybridization techniques, in accordance to the
ASCO/CAP guidelines.
Histone Isolation from FFPE Tissue (Fig. S1A)—Four 10-m tissue
sections (corresponding to 20–60 mg of tissue, as measured by
weighting the tissue after paraffin removal) were deparaffinized by
adding 1 ml of hystolemon (Dasit Group Carlo Erba), vortexing for 30 s
and centrifuging at 18,000  g for 3 min (5 times). The samples were
rehydrated with incubations in decreasing concentrations of ethanol
(100%, 95%, 70%, 50%, 20%, and water) for 3 min at room temper-
ature, followed by centrifugation for 3–5 min at 18,000  g for each
step. Rehydrated FFPE sections were permeabilized in 0.5 ml of
Tris-buffered saline (TBS) containing 0.5% Tween20 and protease
inhibitors for 20 min at room temperature in a rotating platform,
followed by a 5 min centrifugation at 18,000  g. The samples were
then resuspended in 200 l of 20 mM Tris pH 7.4 containing 2% SDS
and sonicated in a Branson Digital Sonifier 250 with a 3 mm microtip
until tissues pieces were homogenized. Proteins were extracted and
de-crosslinked with a 45 min incubation at 95 °C, followed by a 4 h
incubation at 65 °C. Protein concentration was estimated with the
Bio-Rad DC protein assay kit (Bio-Rad, Segrate, Italy) and 16–20 g
of proteins were run on a 17% SDS-PAGE gel following protein
detection with colloidal Coomassie staining (Expedeon, San Diego,
CA) to quantify histone concentration based on a comparison with
known amounts of recombinant histone H3.1 (New England Biolabs,
Ipswich, MA). Acidic extraction, a step typically performed to purify
histones, was omitted because it cannot be performed in the pres-
ence of detergents. Nevertheless, histones represented a good por-
tion of the FFPE protein extract (supplemental Fig. S3B). The repro-
ducibility of the histone isolation protocol was assessed by analyzing
adjacent FFPE sections from the same mouse spleen (supplemental
Fig. S2).
Histone Isolation from Fresh-frozen Mouse Spleen and Liver Tissue
and Breast Cancer Cell Lines (supplemental Fig. S1C-D)—Cells were
obtained from fresh mouse spleen and liver as described above and
histones were isolated as previously described (15) (supplemental Fig.
S1C). Briefly, 30  106 cells were resuspended in lysis buffer (10%
sucrose; 0.5 mM EGTA, pH 8.0; 15 mM NaCl; 60 mM KCl; 15 mM
HEPES; 0.5% Triton; 0.5 mM PMSF; 1 mM DTT; 5 mM NaF; 5 mM
Na3VO4; 5 mM Na-butyrate; protease inhibitors) and nuclei were sep-
arated from the cytoplasm by centrifugation on a sucrose cushion.
Histones were extracted by a 4 hours incubation in 0.4 N HCl at 4 °C
and dialyzed overnight against 100 mM CH3COOH, using dialysis
membranes with a 6–8 kDa cutoff (Spectrum Laboratories, Inc, Ran-
cho Dominguez, CA). The dialyzed samples were lyophilized and
stored at 80 °C. The same procedure was used to isolate histones
from the breast cancer cell lines used to generate the super-SILAC
mix (supplemental Fig.S1D, see below).
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Histone Isolation from Fresh-frozen Human Breast Cancer Tissue
(supplemental Fig. S1B)—Because breast tissue cannot be readily
homogenized to single cells as described above for spleen and liver
tissues and is available in limited amounts, we developed and alter-
native protocol to obtain histones. Twenty to seventy mg of frozen
breast cancer tissue were thawed on ice, cut in pieces as small as
possible with scissors and then homogenized in PBS containing 0.1%
Triton X-100 and protease inhibitors using a Dounce homogenizer.
Tissue debris were removed by filtering the homogenate through a
100 m cell strainer and nuclei were isolated with a 10 min centrifu-
gation at 2300  g. Nuclei were resuspended in 100–200 l of the
same buffer containing 0.1% SDS and incubated for few minutes at
37 °C in the presence of 250 U of benzonase (Merk Millipore, Darm-
stadt, Germany) to digest nucleic acids. No acidic extraction was
performed to avoid samples loss. The concentration of purified his-
tones and nuclei extracts was measured using the Bradford protein
assay kit (Thermo Fisher Scientific) and their purity was assessed by
SDS-PAGE. Yield ranged between 0.5 and 1.3 g of histone octamer
per 10 mg of starting tissue.
Histone Digestion—About 5 g of histones per run per sample
were separated on a 17% SDS-PAGE gel and bands corresponding
to histones H3 and H4 were excised and in-gel digested as previously
described (15). Briefly, gel bands were cut in pieces and destained
with repeated washes in 50% acetonitrile (ACN) in H2O, alternated
with dehydration steps in 100% ACN. Gel pieces were then in-gel
chemically alkylated with D6-acetic anhydride (Sigma-Aldrich) 1:9 in 1
M NH4HCO3, using CH3COONa as catalyzer. After shaking for 3 h at
37 °C, chemically modified gel slices were washed with NH4HCO3,
alternated with ACN at increasing percentages (from 50 to 100). The
in-gel digestion was performed overnight with 100 ng/l trypsin (Pro-
mega) in 50 mM NH4HCO3 at 37 °C, in order to obtain an “Arg-C like”
in-gel digestion that originates histone peptides of optimal length for
MS analysis by cleaving at the C-terminal of arginine residues. Finally,
digested peptides were extracted using 5% formic acid alternated
with ACN 100%. In SILAC experimental set-ups, unlabeled and
heavy-labeled histones were mixed in equal amounts prior to gel
separation, and then processed as described above. Digested pep-
tides were desalted and concentrated using a combination of re-
versed-phase C18/C and strong cation exchange (SCX) chromatog-
raphy on handmade nanocolumns (StageTips). Digested peptides
were then eluted with 80% ACN/0.5% acetic acid and 5% NH4OH/
30% methanol from C18/C and SCX StageTips, respectively. Eluted
peptides were lyophilized, resuspended in 1% TFA, pooled and sub-
jected to LC-MS/MS analysis.
LC-MS/MS—Peptide mixtures were separated by reversed-phase
chromatography on an in-house-made 25 cm column (inner diameter
75 m, outer diameter 350 m outer diameter, 1.9 m ReproSil, Pur
C18AQ medium), using a ultra nanoflow high-performance liquid
chromatography (HPLC) system (EASY-nLC™ 1000, Thermo Fisher
Scientic) connected online to a Q Exactive instrument (Thermo Fisher
Scientific) through a nanoelectrospray ion source. Solvent A was
0.1% formic acid (FA) in ddH2O and solvent B was 80% ACN plus
0.1% FA. Peptides were injected in an aqueous 1% TFA solution at a
flow rate of 500 nl/min and were separated with a 100 min linear
gradient of 0–40% solvent B, followed by a 5 min gradient of 40–
60% and a 5 min gradient of 60–95% at a flow rate of 250 nl/min. The
Q Exactive instrument was operated in the data-dependent acquisi-
tion (DDA) mode to automatically switch between full scan MS and
MS/MS acquisition. Survey full scan MS spectra (m/z 300–1650) were
analyzed in the Orbitrap detector with resolution of 35,000 atm/z 400.
The five most intense peptide ions with charge states  2 were
sequentially isolated to a target value for MS1 of 3  106 and frag-
mented by HCD with a normalized collision energy setting of 25%.
The maximum allowed ion accumulation times were 20 msec for full
scans and 50 msec for MS/MS and the target value for MS/MS was
set to 1  106. The dynamic exclusion time was set to 20 s and the
standard mass spectrometric conditions for all experiments were as
follows: spray voltage of 2.4 kV, no sheath and auxiliary gas flow.
One technical replicate of the breast cancer cell lines profiled to set
up the super-SILAC strategy (see below) was analyzed through HPLC
in combination with a LTQ-Velos Orbitrap. Samples were separated
by nano-liquid chromatography using an EASY-nLC system (Proxeon
Biosystems, Odense, Denmark) on an in-house-made 50 cm column
(inner diameter 75 m, outer diameter 350 m outer diameter, 3 m
ReproSil, Pur C18AQ medium) and analyzed using an LTQ-Velos
Orbitrap instrument (Thermo Fisher Scientific). The solvent composi-
tion were as described above, and peptides were separated with a
shallow gradient at a flow rate of 300 nl/min: 10–50% solvent B over
95 min, 50–60% over 5 min and 60–80% over 5 min. The LTQ-Velos
Orbitrap was operated in DDA mode and MS spectra (m/z range
300–1650) were analyzed with resolution r  30,000 at m/z 400
(transient time  250 ms). The 10 most intense peptide ions with
charge states  2 were sequentially isolated to a target value of 1 
106 and fragmented by CID with a normalized collision energy setting
of 35%. MS/MS settings were: maximum ion injection time 150 ms,
minimum signal threshold 500; isolation width 2 Da; ion target value
1e4, dynamic exclusion time 25 s. Results obtained using the two
LC/MS setups generated very similar results (supplemental Fig. S4C).
Data Analysis—Acquired RAW data were analyzed by the inte-
grated MaxQuant software v.1.3.0.5, which performed peak list gen-
eration and protein identification using the Andromeda search engine
(16). The Uniprot MOUSE 1301 (33202 entries) and HUMAN 1301
(43990 entries) databases were used for peptide identification. En-
zyme specificity was set to Arg-C. The estimated false discovery rate
of all peptide identifications was set at a maximum of 1%. The mass
tolerance was set to 6 ppm for precursor and fragment ions. Three
missed cleavages were allowed, and the minimum peptide length
was set to 6 amino acids. We focused on lysine methylation and
acetylation, including as variable modifications lysine D3-acetylation
(45.0294 Da), lysine monomethylation ( 59.0454, corresponding to
the sum of D3-acetylation (45.0294) and monomethylation (14.016
Da)), dimethylation (28.031 Da), trimethylation (42.046 Da), and
lysine acetylation (42.010 Da). To reduce the search time and the
rate of false positives, which increase with increasing the number of
variable modifications included in the database search (17), the raw
data were analyzed through multiple parallel MaxQuant jobs (18),
setting different combinations of variable modifications: (1) D3-acety-
lation, lysine monomethylation with D3-acetylation, dimethylation and
lysine acetylation, (2) D3-acetylation, lysine monomethylation with
D3-acetylation, dimethylation and trimethylation, (3) D3-acetylation,
lysine monomethylation with D3-acetylation, trimethylation, and lysine
acetylation. In addition, for the mouse samples we included in the
search lysine modifications that may be induced by formalin fixation
(19): formylation (27.9949 Da), methylene adducts (12 Da) and
methylol adducts (30.0106 Da), which were included in a fourth
search job together with D3-acetylation. MaxQuant search results
from different jobs were exported and combined; peptides with An-
dromeda score less than 60 (corresponding to a Mascot score of 15
(16), which has been previously used as a cut-off value (20)) and
localization probability score less than 0.75 (21, 22), were removed.
Modified peptide parameters and representative MS/MS spectra for
each modified peptide are reported in supplemental Table S4 and
supplemental Fig. S8, respectively. Identifications and retention times
were used to guide the manual quantification of each modified pep-
tide using QualBrowser version 2.0.7 (ThermoFisher Scientific, Wal-
tham, MA). Site assignment was evaluated using QualBrowser and
MaxQuant Viewer 1.3.0.5. The mass spectrometry proteomics data
have been deposited to the ProteomeXchange Consortium (23) via
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the PRIDE partner repository with the data set identifier PXD002669.
Extracted ion chromatograms (XIC) were constructed for each doubly
charged precursor based on its m/z value, using a mass tolerance of
10 ppm and a mass precision up to four decimals. For each histone
modified peptide, the relative abundance (RA) was estimated by
dividing the area under the curve (AUC) of each modified peptide for
the sum of the areas corresponding to all the observed forms of that
peptide (24). For SILAC experiments, Arg10 was selected as heavy
label (multiplicity  2) in MaxQuant. The heavy form of each modified
peptide was quantified from its XIC and the relative abundance quan-
tified. L/H ratios of relative abundances were calculated for each
modified peptide (supplemental Fig. S5A). Because we assume that
the sum of all the possible forms of the peptide should be constant in
all the samples, using ratios of relative abundances corrects for
possible errors in mixing light and heavy histones. To better visualize
differences among biopsies the ratio of one sample relative to the
standard was divided by the average ratios across the samples
(supplemental Fig. S5C). As an alternative normalization strategy,
SILAC ratios were obtained from light and heavy AUC values and
were corrected based on the SILAC ratio of an unmodified histone H3
peptides (supplemental Fig. S5B and S5D). The results obtained
using the two normalization strategies were very similar, suggesting
that other possible modifications not specifically indicated in the
database search do not substantially affect the quantification based
on the estimation of %RA. Visualization of hPTM ratios and unsuper-
vised hierarchical clustering were performed using Perseus, set-
ting correlation distance and complete linkage as parameters
(http://www.perseus-framework.org/).
Experimental Design and Statistical Rationale—FFPE and frozen
samples from mouse tissues were acquired in duplicate (technical
replicates for all samples with the exception of spleen samples, for
which two biological replicates were analyzed, see supplemental Data
set S1). FFPE and frozen samples from human breast cancer biopsies
1–3 were acquired in triplicate (technical replicates, see supplemental
Data set S2). The analysis of five patient biopsies for each subtype
allowed assessing differences among breast cancer subtypes (sup-
plemental Data set S3). Differences among L/H ratios for breast
cancer subtypes were analyzed by one-way ANOVA followed by
Bonferroni’s Post-hoc test using GraphPad Prism. Differences be-
tween Luminal A-like and Triple Negative samples were assessed by
T-Test analysis.
Set Up of the Super-SILAC Mix Approach—Breast cancer and
MCF10A cell lines were obtained from ATCC. MCF10A cells were
grown DMEM/Ham’s F12 (1:1) (Lonza, Basel, Switzerland), supple-
mented with 5% dialyzed fetal bovine serum (FBS) (Thermo Fisher
Scientific), 2 mM L-glutamine, 20 ng/ml human epidermal growth
factor, 50 ng/ml cholera toxin, 10 ng/ml human insulin and 0.5 g/ml
human transferrin. Breast cancer cells were grown in SILAC-DMEM
(Euroclone, Pero, Italy) supplemented with 2 mM L-glutamine, 146
mg/l of lysine (Sigma-Aldrich), 84 mg/l L-13C6
15N4-arginine (Arg-10,
Sigma-Aldrich), 10% dialyzed serum (Thermo Fisher Scientific) and
penicillin/streptomycin. Breast cancer cells were cultured for8 dou-
blings in SILAC medium to obtain complete labeling. To identify a
pool of cell lines that would appropriately represent the heterogene-
ous range of modifications possibly found in breast tumor samples,
we analyzed the hPTM patterns of five breast cancer cell lines be-
longing to different subtypes and with different immunoprofiles (sup-
plemental Fig. S4A). For this purpose we used a previously described
spike-in approach (15), where unlabeled normal breast MCF10A cells
are spiked into each of the five heavy-labeled breast cancer cell line
samples and used as an internal standard for quantitation. (supple-
mental Fig. S4B). We evaluated histone H3 hPTM patterns of acety-
lations and methylations of lysine residues based on H/L ratios of
relative abundances (supplemental Fig. S4C–S4D). Because they
showed the most divergent patterns, we chose MDA-MB-231, MDA-
MB-468, MDA-MB-453 and MDA-MB-361 to generate a super-SILAC
mix that can be spiked into breast cancer samples prior to GeLC-MS
analysis (supplemental Fig. S4E). Two set-ups were used for data
acquisition (HPLC coupled with a LTQ-Velos Orbitrap or a uHPLC
combined with a Q Exactive), which gave the same results (supple-
mental Fig. S4C), proving the reproducibility of the results across
different instrument setups. Equal amounts of histones from MDA-
MB-231, MDA-MB-468, MDA-MB-453 and MDA-MB-361 were
mixed, aliquoted, lyophilized and stored at 80 °C until use.
Immunoblot Analysis—FFPE or frozen extracts were separated
by SDS-PAGE, transferred on PVDF membranes and probed by
immunoblotting with anti-H3 K27me3 (Millipore 07–449) and an-
ti-H3 K9me3 (Abcam 8898). An anti-histone H3 antibody (Abcam
1791) was used as loading control. Images were acquired on a
ChemiDoc XRS instrument (Bio-Rad) and quantified using the Im-
ageJ software (rsb.info.nih.gov).
RESULTS
Set-up of the PAT-H-MS Protocol in Mouse Tissues—To
set-up the technology to profile by mass spectrometry hPTMs
from FFPE tissue we used different murine tissues, which can
be obtained in large amounts and offer the possibility to
compare FFPE and frozen tissue from the same samples
stored for up to several years. We analyzed samples obtained
from mouse spleen or liver (to prove the applicability of the
protocol to different tissues) and that were stored in paraffin
for short periods (few weeks) or an extended time (6 years), to
evaluate the effect of storage time. To verify that the hPTMs
found in the FFPE samples are representative of the real
epigenetic status of the tissue, for each sample we used as
control histones purified through a standard protocol from
frozen cells derived exactly from the same tissue and stored
for the same amount of time (Fig. 1A).
Proteins were extracted from FFPE samples using a proto-
col that relies on the presence of high percentages of deter-
gent and the incubation at high temperatures, two factors that
have been shown to be critical to solubilize proteins from
FFPE tissues and to reverse the cross-links generated by
formaldehyde fixation (9). In particular, high concentrations of
SDS have been shown to be the most effective way to pro-
mote the solubilization of proteins from FFPE tissues and their
de-crosslinking. Histones can be obtained from four 10 m-
thick paraffin sections through few straightforward steps: (1)
de-paraffinization and rehydration using standard protocols,
(2) lysis and homogenization by sonication in a high detergent
buffer, (3) protein extraction and de-crosslinking at high tem-
peratures and (4) SDS-PAGE, which removes contaminants
and excess detergent and separates histones from other pro-
teins present in the sample. No further purification steps are
required, as histones represent a considerable portion of the
sample (at least 30% based on protein concentration, Fig.
1A). Based on the comparison with known amounts of his-
tones on a Coomassie-stained SDS-PAGE gel, extraction
from four 10 m-thick paraffin sections of mouse spleen
typically yields 50–90 g of histone octamer (supplemental
Table S1). Histone yield varies considerably among different
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tissues (10–120 g from 30 samples analyzed, supplemen-
tal Table S1), but for all the types of tissues tested the extrac-
tion protocol provided enough material for a full MS-based
characterization of hPTMs, which usually requires 3–4 g of
histone octamer per MS run. We cut gel bands corresponding
to histones H3 and H4 and in-gel digested them, using a
standard procedure that involves chemical alkylation with
deuterated acetic anhydride, followed by trypsin digestion
(25). This procedure allows to obtain from gel bands an
“Arg-C like” digestion that generates histone peptides of op-
timal length for the following analysis by LC/MS/MS, which
was performed through reversed-phase chromatography
coupled to a QExactive instrument. By analyzing the MS raw
files in the software environment MaxQuant we identified all
the most common lysine modifications, plus various less
common ones (Fig. 1B). To examine possible artifacts result-
ing from formalin fixation, in addition to acetylation and meth-
ylation the raw files were searched for lysine formylation and
other lysine modifications induced by formalin (see Experi-
mental Procedures). Although all modifications observed in
frozen samples are maintained in FFPE tissues, we observed
the appearance of spurious methylations on histone H3 K14,
K23 and K37, and on the histone H4 N-terminal tail, and few
formylation sites on peptide H3 27–40 and peptide H4 4–17,
which were absent in the frozen samples.
To estimate the levels of these modifications we quantified
the raw abundance of each modified peptide form using
MS-extracted ion chromatograms and converted it to relative
abundance percentages (%RA) by dividing the area under the
curve of each modified peptide for the sum of the areas
corresponding to all the observed forms identified for that
peptide (24) (supplemental Data set S1, supplemental Table
S2). Out of the fifteen modified peptides present only in FFPE
samples, three had such a low intensity that they could not be
measured, six have a relative abundance 0.25% and four
1%, thus representing a very minor fraction of the total. Ac-
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cordingly, the comparison between FFPE and frozen tissues
showed almost identical relative abundances for the most
common and functionally relevant histone modifications
found in four peptides from histone H3 (3–8, 9–17, 18–26 and
27–49, Fig. 2A). Remarkably, the %RA correlation between
FFPE and frozen tissues for these peptides (r  0.998, p 
0.0001, Fig. 2B) was comparable to the correlation between
histone preparations obtained from adjacent FFPE sections
from the same mouse spleen (r  0.991, p  0.0001, supple-
mental Fig. S2), indicating that the variability between frozen
and FFPE preparations is similar to the technical variability
observed in independently prepared FFPE samples. Analysis
of FFPE samples after long-term storage (6 years) showed (in
comparison to frozen tissues stored for the same time) an
increase in K79me1 and me2 abundance and the appearance
of methylated residues on histone H4 that account for 20%
of the total (supplemental Table S2 and Fig. 2 bottom panel).
These results are likely caused by the storage conditions and
are in accordance with a recent analysis showing that lysine
methylation is the most frequent modification induced by
FFPE preservation (19). Therefore, we excluded peptides H3
73–83 and H4 4–17 from our following analysis, focusing on
four histone H3 peptides carrying functionally relevant post-
translational modifications (3–8, 9–17, 18–26 and 27–40),
which are not affected by long-term storage.
Set-up of a Histone-focused Version of the Super-SILAC
Approach—We next sought to apply this protocol to the
hPTM analysis of clinically relevant samples (breast cancer
primary tumors), combining it with a super-SILAC spike-in
approach to be able to accurately quantify even small modi-
fication changes among patient samples. The stable-isotope
labeling by amino acids in cell culture (SILAC) strategy relies
on differential labeling of cell populations through incorpora-
tion of different isotope-encoded amino acids, which can be
distinguished by MS (26). Because the differentially labeled
samples can be combined early during the MS-proteomics
workflow and are analyzed together by MS, the impact of
experimental variation during sample preparation is reduced
A
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and the accuracy of the quantitation highly improved. Varia-
tions of this technique include the super-SILAC set up, where
a mixture of SILAC-labeled cells is spiked into unlabeled
samples and used as an internal reference, which allows
sample multiplexing and overcomes the intrinsic unfeasibility
of applying SILAC to the analysis of clinical samples (27). In
addition, using a mixture of cell lines instead of a single one
also offers the advantage of better representing the hetero-
geneity found in a complex sample, such as a tumor tissue.
The super-SILAC approach has been successfully used not
only for global proteomic studies, but also to analyze the
phosphoproteome (28), the N-glycosilated secretome (29)
and histones (30). Here, we used a histone-focused version of
the super-SILAC approach to analyze and quantify hPTMs in
breast cancer samples. Based on their different subtypes,
grade of aggressiveness and hPTM patterns (supplemental
Fig. S4), we chose four breast cancer cell lines to generate a
super-SILAC mix that was spiked into breast cancer samples
prior to GeLC-MS analysis and used as an internal reference
(Fig. 3A).
Application of PAT-H-MS in Combination with Super-
SILAC to Accurately Quantify hPTM Changes in Human
Breast Cancer FFPE Samples—We applied the PAT-H-MS
protocol to the analysis of FFPE breast tumor samples from
three patients and compared them to their respective fresh
frozen tissues as control (See supplemental Fig. S3A–S3C for
the molecular characterization of the samples, the SDS-PAGE
gel used to assess the sample purity and the list of the
identified peptides). We obtained histones from frozen breast
cancer tissue by developing a simple extraction protocol that
yields fairly pure histones (75% of the sample based on
protein concentration) in amounts sufficient for MS analysis
from small quantities of starting frozen material (see Experi-
mental Procedures). Confirming the results obtained with
mouse samples, the quantification of the FFPE and the
corresponding frozen tissues showed remarkably similar re-
sults for histone H3 peptides 3–8, 9–17, 18–26 and 27–40
(supplemental Fig. S3D–S3E).
Next, we combined the PAT-H-MS and the super-SILAC
approaches. The output of this type of experiment is repre-
sented by L/H ratios that are a measure of the abundance of
the peptides in each breast cancer primary specimen (light
channel), compared with the super-SILAC mix (heavy chan-
nel). Such ratios were then divided by the average ratio to
better visualize differences among samples (see Experimental
Procedures and supplemental Data set S2). Ratios, and cor-
respondingly hPTM changes among patients, were remark-
ably similar for the two sets of samples that were either frozen
or stored in paraffin (r  0.72, p  0.0001, Fig. 3B–3C). The
majority of the trends were maintained in frozen and FFPE
samples, although a few differences existed, which may also
be ascribed to the fact that distinct tissue portions were
frozen or fixed. Indeed, the heterogeneity of tumor tissues
represents an intrinsic limitation for the analysis of both fresh-
frozen and FFPE tissue, which could be overcome by com-
bining the PAT-H-MS protocol with procedures such as sam-
pling of tumor cores or laser microdissection, to increase
sample homogeneity. Recently, these techniques have been
successfully used for the implementation of pathology tissue
chromatin immunoprecipitation (PAT-ChIP), an approach for
the extraction and high-throughput genomic analysis of
FFPE-derived chromatin that represents the genomic coun-
terpart of our proteomic analysis (6, 7).
Histone Modification Profiling of Breast Cancer Subtypes by
PAT-H-MS—Breast cancer can be divided clinically into four
main subtypes: Luminal A-like and Luminal B-like (expressing
ER and PR), HER2-positive, and Triple Negative. We asked
whether breast cancer tumors show distinct hPTM patterns
and whether a relationship between those patterns and clin-
ical features exist. We quantitated 24 differentially modified
peptides from histone H3 in FFPE bioptic samples from pa-
tients matched for other clinical features (age, sex, etc.) be-
longing to the various subtypes (5 patients/subtype, supple-
mental Table S3). Non-supervised clustering defined four
main clusters characterized by different levels of histone
marks (Fig. 4). Cluster 1, containing mostly Luminal A-like
samples, shows elevated levels of histone H3 K27me3,
K27me3/K36me1, and K27me2/K36me1 and low levels of
K9me3, K9me3/K14ac, K36me1, K36me2, and K27me1. As-
sociation between elevated K27me3 and Luminal A-like tu-
mors has been reported in several immunohistochemistry
(IHC) studies (31, 32), thus providing an indirect validation for
our method. Cluster 3, which contains four out of five of the
Triple Negative samples and three HER samples, shows
opposite trends for these modifications. Two additional clus-
ters (Cluster 2 and 4) comprise four Luminal B-like samples,
two HER samples and one Triple Negative. Similarly to
Cluster 1, Cluster 2 shows increased levels of K27me2 and
me3, but in addition also presents elevated levels of peptides
containing acetylation either on K18 or K23 (K18(23)ac) and
K27me1/K36me3, whereas Cluster 3 has higher levels of
K27me1/K36me1 and K27me2/K36me2 compared with the
other clusters, with intermediated levels of K27me3. A more
in-depth analysis revealed a remarkable difference in hPTM
levels in particular among Luminal A-like and Triple Negative
breast cancer samples (Fig. 4B and supplemental Fig. S6). We
analyzed the FFPE extracts corresponding to these two sub-
types (LuA 1–5 and TN 1–5) by Western blot analysis (Fig.
4C–4D), confirming the lower levels of K27me3 in Triple Neg-
ative samples through a different methodology. A similar trend
was observed also by IHC analysis of the same samples
(supplemental Fig. S7) and in additional frozen samples be-
longing to the same subtypes (Fig. 4E–4F). Interestingly, no
significant differences were observed in any of these anti-
body-based assays for the K9me3 mark, for which PAT-H-MS
showed quantitative differences of smaller amplitude (Fig. 4
and data not shown). We surmise that the MS-based method
developed here may be more powerful in detecting small
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differences among samples compared with traditional anti-
body-based assays, that are by nature semi-quantitative
and unable to detect faithfully small differences among
samples, and that the observed difference in this residue
measured by PAT-H-MS reflects a subtle, but real differ-
ence among samples.
DISCUSSION
Drugs targeting enzymes able to modify chromatin by mod-
ifying histones are now in clinical use, and several more are at
a clinical stage of drug development. A better understanding
of the molecular mechanisms underlying epigenetic altera-
tions in tumors is of great relevance to optimize the use of
these drugs. To achieve this goal, better tools to explore the
epigenome (globally and locally) have to be developed, to
access efficiently patient samples.
Our results demonstrate for the first time the feasibility to
perform a comprehensive, unbiased and quantitative MS-
analysis of histone PTM patterns on patient samples prepared
for routine pathology investigations, which had been re-
stricted to antibody-based methods so far. Comparisons with
fresh frozen-tissues show that most of the commonly ana-
lyzed histone H3 lysine acetylations and methylations are
qualitatively and quantitatively preserved in FFPE tissues up
to several years old, with the exception of histone H3 peptide
73–83. Few formalin-induced lysine modifications, mostly
methylations, appear in FFPE samples stored for 6 years.
However, the majority of these modifications represent a mi-
nor fraction of the total and do not substantially affect the
relative quantification of the most common modifications
found on histone H3 peptides 3–8, 9–17, 18–26, and 27–40,
on which we focused our analyses. Therefore, our extraction
protocol allows the identification and quantification of at least
24 distinct histone peptide forms, even after prolonged stor-
age of FFPE samples. Because mild changes may be ob-
served after 6 years of storage in paraffin also in a few of the
24 modified histone forms that we focused on, the detection
of small differences (1.5 fold) among samples may benefit
from selecting samples from “storage age-matched” speci-
mens. Importantly, the required starting material is absolutely
compatible with what is available from most biobanks, further
supporting its possible implementation in clinical research/
use.
The PAT-H-MS approach provides several advantages
compared with the traditional antibody-based methods nor-
mally employed in the clinic for hPTM analysis. First, tens of
modifications can be detected in a single MS run, including
modifications for which reliable antibodies do not exist. This
also reduces the amount of starting material needed to obtain
a comprehensive view of hPTM patterns. Second, hPTMs can
be accurately quantified, particularly when spike-in stand-
ards, such as a super-SILAC mix, are used as internal refer-
ence. Using an internal standard also facilitates sample mul-
tiplexing and allows to reliably analyze samples even over
long periods of time, a conceivable scenario when testing a
large clinical dataset. Finally, PAT-H-MS can detect combi-
nations of modifications, which may help defining modifica-
tion signatures of pathological states with improved predictive
power as compared with single biomarkers.
As a proof-of-principle demonstration, we used the PAT-
H-MS approach in combination with a super-SILAC experi-
mental set-up to profile hPTM changes in a clinical collection
of human breast cancer biopsies belonging to different sub-
types. In line with previous studies (31, 32), we observed that
histone H3 K27me3, alone or in combination with K36me1,
was higher in Luminal A-like samples compared with other
subtypes and was particularly low in samples belonging to
Cluster 3, which contains Triple Negative and HER2 samples.
This result provides the proof of concept that PAT-H-MS can
be used to extract clinically relevant information from patient
samples. Most of the Triple Negative samples were grouped
in Cluster 3. In addition to a decreased level in K27me3-
containing peptides, this cluster showed an increase of
K9me3, alone or in combination with K14ac. Interestingly, the
samples belonging to Cluster 3 have the highest levels of Ki67
expression among the samples tested (supplemental Table
S3), possibly linking the hPTM signature observed in this
group with highly proliferating tumors. Consistent with this
hypothesis, the only Triple Negative sample that falls into a
different cluster has a much lower Ki67 expression than the
other samples belonging to the same subtype (supplemental
Table S3).
Triple-negative breast cancers represent a highly diverse
group of cancers, for which well-defined molecular targets
have not yet been identified and targeted therapies do not
exist. Given the heterogeneity of this group of cancers, it was
somewhat surprising to observe that four out of five of the
Triple Negative samples that we analyzed were rather homo-
geneous in their hPTM patterns, and in particular showed
lower levels of the K27me3 mark and increased levels of the
K9me3 and K36me1 marks. The analysis of a larger cohort of
breast cancer patients is ongoing, and will determine whether
the histone marks found in this study can help distinguishing
Triple Negative samples from other breast cancer subtypes. In
addition, because altered levels of histone marks are often
associated with deregulation of histone modifying enzymes,
our findings may suggest candidate epigenetic targets for the
treatment of Triple Negative cancers. For instance, the ele-
vated levels of K9me3 and K36me1/me2 that we observed
may be linked to the deregulation of members of the JMJD2
cluster, which demethylate both of these marks (33).
The set-up used in this experiment could be also readily
employed in extended patients cohorts to discover epigenetic
marks linked with patient outcome, cancer staging or other
clinical features in breast cancer as well as any other diseases
where epigenetic components might play a role. In conclu-
sion, by combining the strengths of MS-based hPTM analysis
with the vast clinical information associated with FFPE sam-
Pathology Tissue Quantitative MS Analysis of Histone PTMs
Molecular & Cellular Proteomics 15.3 875
ples, PAT-H-MS represents a significant technological ad-
vancement in the field of clinical epigenetics. We thus envi-
sion that it will contribute to epigenetic and clinical research
by facilitating the identification of epigenetic biomarkers po-
tentially useful for the management of cancer and other
diseases.
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